Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Co.'s primary product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta. Co. is developing REN001 in rare genetic diseases that typically present with myopathy and have high unmet medical needs, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The RPHM average annual return since 2021 is shown above.
The Average Annual Return on the RPHM average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RPHM average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RPHM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|